Navigation Links
BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
Date:2/27/2013

LYNBROOK, N.Y., Feb. 27, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S., announced today that BioSpecifics' President, Tom Wegman , will present at the following upcoming investor conferences.

  • Cowen and Company 33rd Annual Health Care Conference (Boston, MA)
    Wednesday, March 6, 2013 at 8:40 a.m. EST

  • ROTH Capital Partners 25th Annual Conference (Laguna Niguel, CA)
    Monday, March 18, 2013 at 5:00 p.m. PDT (8:00 p.m. EDT)

The live webcasts of these presentations can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Injectable collagenase is currently marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is approved for Dupuytren's contracture in the European Union, Switzerland and Canada. XIAFLEX is also in clinical development for the treatment of several additional promising indications. A supplemental Biologics License Application is currently under standard review at the U.S. Food and Drug Administration for XIAFLEX for the potential treatment of Peyronie's disease. Auxilium is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials. Auxilium is currently partnered with Asahi Kasei Pharma Corporation for the development and commercialization of injectable collagenase for Dupuytren's contracture and Peyronie's disease in Japan and with Actelion Pharmaceuticals Ltd. for these same indications in Canada, Australia, Brazil and Mexico. Pfizer Inc. has marketing rights to XIAPEX® (the EU trade name for XIAFLEX) for Dupuytren's contracture in 46 countries in Eurasia through April 24, 2013.  For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
3. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
4. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
6. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
7. Medical Equipment Suppliers in Good Health - Research Report on Bruker Corporation, Agilent Technologies Inc., General Electric Company, Becton, Dickinson and Co. and Thermo Fisher Scientific Inc.
8. Medisafe 1 Technologies One-Time Special Dividend Announced
9. Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies, Finds Frost & Sullivan
10. Leading Breast Surgeons Highlight Techniques and Visualization Technologies for Improved Clinical and Aesthetic Outcomes at Invuitys Surgeon Educational Symposium
11. TOA Technologies mobile healthcare service solutions unite personalized service and efficiency to deliver an enhanced patient experience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2020)... ... February 21, 2020 , ... Nationwide jails are seeing higher ... While someone with a mental illness is no more likely to commit a crime ... trespass, loitering, or harassment. , They may be experiencing symptoms that lead to ...
(Date:2/21/2020)... ... ... The business of healthcare management is complex. From providing the best care ... digital and physical safety, there are many things to keep up with. Very often, ... excited to provide their insights on healthcare facility maintenance to attendees at the ...
(Date:2/20/2020)... ... February 20, 2020 , ... Amada Senior Care of Long ... care from trained and knowledgeable Amada caregivers. From day one of opening, owners ... client’s unique needs, preferences and desires, all with the goal of delivering the ...
Breaking Medicine Technology:
(Date:2/21/2020)... ... 21, 2020 , ... Isagenix International , a global ... and final round of Canada finalists for its annual total-body transformation program, the ... Ontario; Taiya Farrell of Winnipeg, Manitoba; Véronique Collin of Orleans, Ontario; and James ...
(Date:2/20/2020)... ... 2020 , ... R3 Stem Cell, the nation's leader in regenerative therapies and ... stem cell procedures on military veterans in 2019. The veterans traveled from all ... R3 Stem Cell Training Course for doctors , providers of all kinds learn how ...
(Date:2/20/2020)... , ... February 20, 2020 , ... ... has a new release with next generation API integration functionality which enables ... VisitorsCoverage Inc. in 2017, TMQuotes was the first white label software-as-a-service ...
(Date:2/19/2020)... ... February 19, 2020 , ... Drs. Richard Amato, Michael ... of Connecticut, celebrate 30 years of serving Monroe, CT with a “Throwback Special” ... they charged in 1989, only thirty dollars. To further serve their patients, they ...
(Date:2/19/2020)... ... February 19, 2020 , ... Actor, director, and producer, ... known for his acting abilities demonstrated in blockbuster hits like the “John Wick” ... Scenes” with Laurence Fishburne. “Behind The Scenes” features a broad array of topics. ...
Breaking Medicine News(10 mins):